Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.